MarketInOut Stock Screener Log In | Sign Up
 

Erasca Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Erasca Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,910.66 mln
Float247 mln
Earnings Date11/11/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

24.11
Transformational upside

Relative Strength

24 / 100
Significantly lagging

Debt / Equity

0.12
Very low leverage

ROE

-79.75
Deeply negative

ROA

-66.19
Deeply negative

Business Description

Erasca is a San Diego-based company founded in 2018 that develops cancer treatments targeting a specific genetic pathway, known as RAS/MAPK, which drives the growth of many tumors. The company has several treatments in development, including therapies aimed at different mutations within this pathway, and works with a number of partners around the world to research, manufacture, and bring these treatments to market. Erasca's goal is to give patients with these hard-to-treat cancers more effective and precisely targeted options.

Key Fundamentals

EPS-0.95
ROE-79.75
ROIC-93.23
ROA-66.19
EBITDA, mln-284
EV / EBITDA-17.17
EV / EBIT-16.99

Quote Details

Last 14.39
Change 0.35 (2.49%)
Open 13.99
Volume 3,498,640
Turnover 50,345,432
Average Volume 4,991,636

Financial Ratios

Leverage Ratio1.20
Current Ratio8.29
Price / Book12.64
Price / Tangible Book12.64
Debt / Equity0.12

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price24.11
Short Ratio7.32
Short % of Float11.18

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 7.47% 92 / 100   
1 Month -0.9% 58 / 100   
2 Months -23.54% 20 / 100   
6 Months -33.04% 19 / 100   
1 Year 534% 100 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog